Stakeholders in the pharmaceutical sector have warned that Nigeria’s heavy reliance on imported Active Pharmaceutical Ingredients (APIs) poses a critical threat to the nation’s medicine security.
The warning was delivered during a stakeholder meeting in Abuja aimed at accelerating the shift to domestic active pharmaceutical ingredients (APIs) production for priority essential medicines. The session was organised by Nigeria Health Watch in partnership with the World Bank Group.
While Nigeria maintains a growing number of pharmaceutical companies capable of manufacturing finished medicines, the industry remains structurally vulnerable. Most local manufacturers currently depend on foreign-sourced raw materials and APIs to produce the final medicinal products consumed in the country.
Reducing dependency on foreign raw materials
The current manufacturing model in Nigeria creates a disconnect between the production of finished drugs and the chemical components required to make them. This reliance leaves the domestic supply chain exposed to global market volatility, international shipping disruptions, and fluctuations in the foreign exchange market.
Industry experts at the meeting emphasised that even though local plants can package and formulate drugs, the absence of domestic API production means that any disruption in the global supply of ingredients—from major producers like India or China—could lead to immediate shortages of essential medicines in Nigerian hospitals and pharmacies.
The meeting focused on the urgent need to incentivise the local production of ingredients for priority essential medicines. By localising the production of these core components, stakeholders argue that Nigeria can insulate its healthcare system from external shocks and reduce the overall cost of medicines for citizens.
The partnership between Nigeria Health Watch and the World Bank Group seeks to address these systemic gaps by fostering a more resilient pharmaceutical ecosystem. The shift toward domestic API manufacturing is seen as a necessary step to move beyond simple drug formulation and towards true pharmaceutical industrialisation.
The immediate focus for the involved institutions remains the development of frameworks that encourage investment in API manufacturing plants and the establishment of regulatory support to ensure locally produced ingredients meet international quality standards.
Explore more News stories from Business Elites Africa.



